Chordia Therapeutics
Chordia Therapeutics is a Fujisawa, Japan-based biotechnology company developing novel small-molecule cancer therapies that target RNA regulatory stress. Its lead candidate, the CLK inhibitor CTX-712, is in Phase 1 clinical trials. Founded in November 2017 as a spinout from Takeda Pharmaceutical, the company listed on the Tokyo Stock Exchange Growth Market in June 2024.
Company Facts
- Headquarters: Fujisawa, Japan
- Founded: 2017
- Employees: 21
- Type: public
- Website: https://www.chordiatherapeutics.com
- Industries: Biotechnology, Oncology, Drug Discovery
Key People at Chordia Therapeutics
- Masaru Okatani — Chief Financial Officer
- Yoshiyuki Tanaka — Chief Medical Officer
- Hiroshi Miyake — Chief Executive Officer